PAR-25-369 ELSI R21 eligibility Guide
Updated 13 official sources
Quick Answer: PAR-25-369 is the NIH ELSI R21 route for exploratory or developmental research on ethical, legal, and social implications of human genetics and genomics.
Full answer and how we checked it
It is clinical trial optional and fits early, high-value questions that can be answered within R21 scope. The 2026 decision turns on 7 checks.
Who this is for: Bioethics researchers, genomics teams, legal scholars, social scientists, public health researchers, genetic counseling teams, and sponsored-research offices deciding whether an ELSI R21 is the right route.
Data note: This guide uses NIH PAR-25-369, the NHGRI ELSI program page, Grants.gov listing 358176, NIH RePORTER, and Grantsights award-data signals. Due dates and companion NOFO expirations were confirmed on October 1, 2026, and RePORTER awards on October 6, 2026.
In this guide
- Source Check
- If the October 20 Date Is Out of Reach
- What the ELSI R21 Asks For Beyond the Science
- How ELSI R21 Applications Are Reviewed
- 7 PAR-25-369 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- Who the ELSI R21 Has Funded: 13 Projects Since FY2021
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This R21 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day ELSI R21 Readiness Plan
- 5 Final Research Checks Before Submission
- 7 ELSI R21 Checks Before October 20, 2026
- Sources
According to NIH in PAR-25-369 (opens in a new tab), this NOFO invites R21 applications studying ethical, legal, and social implications of human genetic or genomic research. The route is broad by discipline, but the genomics connection has to be real.
The decision question is whether the project has an exploratory ELSI question that can be answered in two years, or whether it needs a larger R01, smaller R03, or non-ELSI social science route.
Use this guide with the live NIH ELSI R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Family Health R01 guide, and the Grantsights grant database.
Source Check
Checked October 2026.
As of October 1, 2026, PAR-25-369 (opens in a new tab) has one cycle left. October 20, 2026 is the last date for new applications and November 18, 2026 the last for resubmissions. Whichever date a team uses, review comes in March 2027, council in May, and money no sooner than July 2027. The NOFO expires November 19, 2026, and applications are due by 5 p.m. local time.
The two companion ELSI NOFOs end in the same window. The R03, PAR-25-370 (opens in a new tab), expires November 17, 2026, and the R01, PAR-25-371 (opens in a new tab), expires November 19, 2026. None of the three had a posted reissue in the NIH Guide on October 1, 2026.
The budget rule is broader than a two-year-only summary. NIH says application budgets are limited to a combined total of no more than $275,000 in direct costs for a two- or three-year project period, with no more than $200,000 in direct costs in any single year. NIH also says applicants should review participating institute and office interest areas and contact scientific staff before initiating application plans.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
If the October 20 Date Is Out of Reach
A team that cannot be ready for October 20 has 2 realistic options. The first is to wait for the next ELSI NOFO. Grants.gov lists a forecast, PAR-28-028, "Research on the Ethical, Legal and Social Implications (ELSI) of Genomics" (opens in a new tab), posted June 3, 2026, saying NHGRI intends to publish a NOFO with an estimated posting date of November 2, 2026 and an estimated application due date of February 16, 2027. A forecast isn't a NOFO: the dates can move, and the forecast doesn't say whether the new notice will include an R21, so treat it as a planning signal, not a deadline. Watch it alongside the NHGRI ELSI funding page (opens in a new tab), which lists the ELSI NOFOs NHGRI uses. The second is the parent R21. That page lists PA-25-304 (opens in a new tab), the parent R21 for projects without a clinical trial, which NHGRI participates in. It uses the standard February 16, June 16, and October 16 dates through October 16, 2027 and expires January 8, 2028.
The parent route has a cost. PA-25-304 does not allow clinical trials, caps the project at 2 years instead of 3, and lacks the ELSI-specific language that tells reviewers to expect conceptual, legal, and normative methods. An ELSI project sent there needs to explain its methods to a broader review audience.
| Route | Budget | Last or next date | Expires |
|---|---|---|---|
| ELSI R21, PAR-25-369 | $275,000 direct over 2 or 3 years, $200,000 cap per year | October 20, 2026 new; November 18, 2026 resubmission | November 19, 2026 |
| ELSI R03, PAR-25-370 | $50,000 direct per year for 2 years | Same October 2026 cycle | November 17, 2026 |
| ELSI R01, PAR-25-371 | Not capped; must match project needs; up to 5 years | Same October 2026 cycle | November 19, 2026 |
| Parent R21, PA-25-304 | $275,000 direct over a 2-year maximum, $200,000 cap per year | October 16, 2026, then February 16, 2027 | January 8, 2028 |
NIH also notes that not every institute in the R21 participates in the R01 or R03. Check the participating list before moving a project to a companion mechanism.
What the ELSI R21 Asks For Beyond the Science
Three requirements in PAR-25-369 are easy to miss because they sit outside the Research Strategy.
- A Resource Sharing Plan for every application. Regardless of budget, NIH wants a plan that says how findings and products such as publications, meeting reports, software, websites, or research tools will reach relevant communities and stakeholders, with a timeline, the platforms used, and the person responsible.
- Budgeted sharing costs. Budgets should include the cost of the Data Management and Sharing Plan and the Resource Sharing Plan. Projects that generate genomic data from participants should also budget for NIH and NHGRI Genomic Data Sharing expectations, such as consent for future research use and broad sharing.
- Paid roles for community partners. Community involvement is allowed, not required. When community members or stakeholders serve as team members or advisors, the budget justification should describe their research roles and the budget support for them.
How ELSI R21 Applications Are Reviewed
R21 review weighs ideas over data. The NOFO says an R21 need not have extensive background or preliminary information, and that reviewers will emphasize the conceptual framework, the level of innovation, and the potential to advance knowledge. Preliminary data are optional, and justification can come from literature or data from other sources.
That changes how a legal or normative project should open. A strong first page states the genomic practice, the unresolved ethical or legal question, and the analytic framework, rather than spending space on pilot results the mechanism does not require. NIH may discuss only the applications judged most meritorious, generally the top half, so a clear framework matters for getting scored at all.
7 PAR-25-369 Eligibility Stop Checks
| Stop check | Strong ELSI R21 signal | Red flag |
|---|---|---|
| Genomics link | Human genetic or genomic research is central | General ethics project |
| ELSI question | Ethical, legal, or social issue drives aims | ELSI is a side paragraph |
| Exploratory scope | R21 can answer the question | Full R01 hidden inside |
| Methods | Empirical, normative, legal, historical, or mixed methods are defined | Methods are vague |
| Stakeholders | Affected groups or decision makers are identified | Population relevance is abstract |
| Trial status | Optional and justified | Trial status unclear |
| Next route | R01, policy, practice, or stop decision is visible | No use for findings |
ELSI applications can struggle when genomics is only context. The route works best when the genomic issue creates the ethical, legal, or social problem.
5 Source Facts Applicants Should Know
According to NIH in PAR-25-369 (opens in a new tab), the funding number is PAR-25-369, the mechanism is R21, clinical trials are optional, and the source expires November 19, 2026. According to the NHGRI ELSI program page (opens in a new tab), ELSI research addresses ethical, legal, and social issues arising from genomics.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-369 |
| Mechanism | R21 exploratory/developmental grant |
| Clinical trial status | Optional |
| R21 budget | Up to $275,000 direct costs over 2 or 3 years |
| Last new date | October 20, 2026 |
| Last resubmission date | November 18, 2026 |
| Expiration | November 19, 2026 |
Who the ELSI R21 Has Funded: 13 Projects Since FY2021
Grantsights checked PAR-25-369 and the 3 ELSI R21 notices before it against NIH RePORTER award records on October 6, 2026. The R21 ran as PA-17-446 (opens in a new tab), then PAR-20-255 (opens in a new tab), then PAR-23-294 (opens in a new tab), which NIH reissued as PAR-25-369 on January 13, 2025. A search of the NIH RePORTER project API (opens in a new tab) by those 4 funding opportunity numbers returned 13 new ELSI R21 projects that started in FY2021 through FY2026.
| Fiscal year | New ELSI R21 projects | Notice | Recipients |
|---|---|---|---|
| 2021 | 3 | PA-17-446, PAR-20-255 | University of Washington, University of Rochester, UCLA |
| 2022 | 3 | PAR-20-255 | Boston Children's Hospital, Arizona State University, University of Pennsylvania |
| 2023 | 1 | PAR-20-255 | Children's Hospital Los Angeles |
| 2024 | 4 | PAR-20-255 | Wake Forest University Health Sciences, Research Triangle Institute, IHC Health Services, Sloan-Kettering Institute for Cancer Research |
| 2025 | 1 | PAR-23-294 | University of North Carolina at Chapel Hill |
| 2026 | 1 | PAR-25-369 | Baylor College of Medicine |
Grantsights analysis of these NIH RePORTER records points to 3 facts that should shape the route choice.
- The R21 is a narrow channel. Since FY2021 it hasn't produced more than 4 new projects in a fiscal year, and it produced 1 in each of FY2025 and FY2026. In FY2026, the ELSI R01 started 9 new projects, 8 under PAR-25-371 (opens in a new tab) and 1 under its predecessor PAR-23-293, and the ELSI R03 started 1. RePORTER doesn't show application counts, so this isn't a success rate, but it does show where ELSI money went. For comparison, the NIH R21 winners page counts 1,521 new R21 awards across NIH in FY2025, against 1 ELSI R21 that year.
- Full projects land near $430,000. Summing every RePORTER record per project, the 13 projects received $388,750 to $486,750 each in total costs, with a median of $429,000. Specifically, Baylor College of Medicine's misattributed parentage study (opens in a new tab) carries $440,000, including $275,000 in direct costs, on one FY2026 record that covers September 2026 through August 2028. The projects that started in FY2021 and FY2022 were paid in yearly pieces instead, so check whether a peer's first-year figure is the whole award before using it as a benchmark.
- NHGRI isn't the only funder. NHGRI administers 10 of the 13, while NIA, NCI, and NIAID administer 1 each. UNC's ELSI study of the human virome (opens in a new tab), for instance, is a $427,625 NIAID award. A project tied to another participating institute's mission can find a home there.
If the project is already close to R01 scope, apply to the ELSI R01, the best bet in this family on FY2026 volume; it runs on the same October 2026 cycle. If it truly needs exploratory work first, the parent R21 guide covers PA-25-304, the backup if the forecasted PAR-28-028 doesn't include an R21.
What NIH Doesn't Tell You
Within 21 days, answer 5 practical questions. First, ELSI review can be unforgiving when the genomic issue is vague. A project about trust, consent, or access needs to say why genomics changes the question.
Second, methods matter. For example, one university in Georgia studying return of polygenic risk scores in community clinics should not rely on general interview language. It should name sampling, analytic approach, stakeholder groups, and decision use.
Third, R21 scope is small. Don't use this route for a national, multi-year policy research agenda unless the project has a narrow developmental question.
Fourth, clinical trial optional does not mean every human-participant design is a good fit. Resolve NIH trial status before selecting forms.
Fifth, timing now limits scope. With October 20, 2026 as the last new-application date, an idea that still needs months of methods work belongs in a later cycle on a reissued or parent route.
6 Evidence Assets That Make This R21 Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the genomics trigger statement: what specific genomic practice, data type, test, result, research use, or policy creates the ELSI issue?
Asset 2 is the stakeholder map. Include participants, patients, families, communities, clinicians, researchers, laboratories, payers, regulators, or policymakers as relevant.
Asset 3 is the methods memo. State whether the project is empirical, normative, legal, conceptual, historical, or mixed method.
Asset 4 is the R21 feasibility table. Include recruitment, data sources, legal sources, analysis, timeline, and outputs.
Asset 5 is the impact pathway. Say whether the result informs policy, consent, disclosure, data sharing, clinical practice, community governance, or future R01 work.
Asset 6 is the adjacent-route comparison. ELSI R01 and R03 routes may fit better depending on scope.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-369 R21 | Exploratory genomics ELSI question fits 2 or 3 years | Route fits |
| ELSI R01 | Project is mature and larger scale | Bigger route may fit |
| ELSI R03 | Question is small and focused | Lower-cost route may fit |
| Parent R21 | Genomics link is weak | Broader route may be cleaner |
| Policy or foundation route | Work is advocacy or implementation only | NIH may not fit |
The best applications can say why R21 is enough and not too much.
6 Bad-Fit Signals
First, genomics is not central. Second, ELSI is an add-on to a scientific study. Third, methods are unclear.
Fourth, stakeholders are not identified. Fifth, the project is too large for R21 scope. Sixth, there is no clear use for findings.
Those stop checks improve trust because users can see when to leave the page and choose another route.
21-Day ELSI R21 Readiness Plan
Days 1 through 3 should confirm source status, deadline, clinical-trial status, budget, and companion routes. Days 4 through 7 should write the genomics trigger statement.
Days 8 through 12 should build the stakeholder and methods plan. Days 13 through 16 should map outputs and impact. Days 17 through 21 should compare R21, R01, R03, parent routes, and non-NIH options.
5 Final Research Checks Before Submission
Within 21 days, finish 5 final research checks. Check 1 is the genomics trigger. The application should name the test, dataset, return-of-results process, sequencing use, family communication issue, or research practice that creates the ELSI question. If the issue would be the same without genomics, this route may be wrong.
Check 2 is methods fit. ELSI R21 proposals can use several methods, but each aim needs a method that can answer it. Aims that promise legal analysis, interviews, community work, and policy output in two years should be narrowed. It's better to win a focused R21 than to submit a thin R01 inside an R21 package.
Check 3 is stakeholder specificity. Name the people affected, such as patients, families, clinicians, or community members, and say how they will shape the work.
Check 4 is clinical-trial status. "Optional" is not a shortcut. We've added the trial-status reminder because forms and review expectations change when the project meets the NIH clinical trial definition.
Check 5 is the companion-route memo. The user should compare R21, R01, R03, parent mechanisms, foundation support, and policy research routes before drafting. You're not done when the topic sounds ethical and genomic. You're done when the scope, method, route, and next use all line up.
7 ELSI R21 Checks Before October 20, 2026
PAR-25-369 has one cycle left, so run these 7 checks before the team commits to it. Each row comes from PAR-25-369 (opens in a new tab) or from the RePORTER check above.
| Check | What to confirm | Where it comes from |
|---|---|---|
| Genomics trigger | A named genomic test, dataset, result, or research practice creates the ELSI question | PAR-25-369 purpose |
| Date | October 20, 2026 for new applications or November 18, 2026 for resubmissions, by 5:00 PM local time | PAR-25-369 key dates |
| Budget | $275,000 direct over 2 or 3 years, with no more than $200,000 in any single year | PAR-25-369 award budget |
| Sharing costs | A Resource Sharing Plan, plus budget lines for it and for the Data Management and Sharing Plan | PAR-25-369 |
| Institute fit | NHGRI or another participating institute; 3 of the 13 funded projects since FY2021 went to NIA, NCI, or NIAID | NIH RePORTER, October 6, 2026 |
| Award size | Funded projects totaled $388,750 to $486,750 in total costs, median $429,000 | NIH RePORTER, October 6, 2026 |
| Fallback | ELSI R01 if the project is near R01 scope; forecasted PAR-28-028 (est. Feb 16, 2027 due date); parent R21 PA-25-304 if the new notice has no R21 | Route table above |
Sources
- NIH PAR-25-369 (opens in a new tab)
- NHGRI ELSI Research Program (opens in a new tab)
- Grants.gov listing 358176 (opens in a new tab)
- NIH PAR-25-370 ELSI R03 (opens in a new tab)
- NIH PAR-25-371 ELSI R01 (opens in a new tab)
- NIH PA-25-304 parent R21 (opens in a new tab)
- NIH PAR-23-294 (opens in a new tab), PAR-20-255 (opens in a new tab), and PA-17-446 (opens in a new tab), the earlier ELSI R21 notices
- NIH RePORTER project search API (opens in a new tab), queried October 6, 2026 for the 4 ELSI R21 notices and the ELSI R01 and R03 notices
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open ELSI R21 record
Check PAR-25-369, June and October 2026 new dates, R21 budget, and clinical-trial optional status.
Compare genomics R01
Use when the genomics data question has grown beyond exploratory R21 scope.
Compare family health R01
Use when the project is family-risk research rather than a genomics ELSI route.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-369 fund?
It funds R21 exploratory or developmental research on ethical, legal, and social implications of human genetic or genomic research.
Are clinical trials allowed?
Yes. PAR-25-369 is clinical trial optional.
What budget applies?
PAR-25-369 allows up to $275,000 in direct costs over a two- or three-year project period, with no more than $200,000 in any single year.
What is the next deadline?
October 20, 2026 is the last new-application date and November 18, 2026 the last resubmission date. PAR-25-369 expires November 19, 2026. No reissue was posted in the NIH Guide as of October 1, 2026, but Grants.gov carries a forecast for PAR-28-028, an NHGRI ELSI of genomics NOFO with an estimated posting date of November 2, 2026 and an estimated due date of February 16, 2027. Those are forecast dates, and the activity codes aren't confirmed yet.
Who should skip this route?
Skip it if genomics is not central, the project is not exploratory, or the ethics and social questions are only an add-on.
Last updated October 12, 2026. Corrected October 11, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
maternal pediatric pharmacology R21 eligibility Guide
PAR 25 111 maternal pediatric guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-357 NEI Secondary Data R21 Eligibility Guide
NIH PAR-25-357 guide: NEI secondary-data R21 eligibility, clinical-trial-not-allowed fit, data readiness, manuscript milestones, and review checks.
PAR-25-266 newborn screening R21 eligibility Guide
PAR 25 266 newborn screening guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PA-25-304: NIH Parent R21 (Clinical Trial Not Allowed)
PA-25-304 is NIH's parent R21 with no clinical trial: $275,000 over 2 years, 21 institutes. Next due Nov 16, 2026 and Feb 16, 2027; expires Jan 8, 2028.
RFA-TR-25-002 Rare Disease R21 Eligibility Guide
RFA-TR-25-002 rare disease preclinical R21 guide: June 2, 2027 deadline, clinical-trial status, budget caps, model-readiness checks, and bad-fit rules.
RFA-DA-26-056 Existing Data R21 Eligibility Guide
RFA-DA-26-056 guide: $275,000 R21 for existing substance-use data, no new data collection, December 3, 2026 due date, and 13 funded awards.